288 related articles for article (PubMed ID: 29706175)
1. Trends and disparities in receipt of pharmacotherapy among pregnant women in publically funded treatment programs for opioid use disorder in the United States.
Short VL; Hand DJ; MacAfee L; Abatemarco DJ; Terplan M
J Subst Abuse Treat; 2018 Jun; 89():67-74. PubMed ID: 29706175
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with receipt of medication for opioid use disorder among pregnant individuals entering treatment programs in the U.S.
Curran L; Manuel J
Int J Drug Policy; 2024 Apr; 126():104342. PubMed ID: 38479161
[TBL] [Abstract][Full Text] [Related]
3. Substance use, treatment, and demographic characteristics of pregnant women entering treatment for opioid use disorder differ by United States census region.
Hand DJ; Short VL; Abatemarco DJ
J Subst Abuse Treat; 2017 May; 76():58-63. PubMed ID: 28161143
[TBL] [Abstract][Full Text] [Related]
4. Medications for opioid use disorder among pregnant women referred by criminal justice agencies before and after Medicaid expansion: A retrospective study of admissions to treatment centers in the United States.
Winkelman TNA; Ford BR; Shlafer RJ; McWilliams A; Admon LK; Patrick SW
PLoS Med; 2020 May; 17(5):e1003119. PubMed ID: 32421717
[TBL] [Abstract][Full Text] [Related]
5. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
Hadland SE; Wharam JF; Schuster MA; Zhang F; Samet JH; Larochelle MR
JAMA Pediatr; 2017 Aug; 171(8):747-755. PubMed ID: 28628701
[TBL] [Abstract][Full Text] [Related]
6. National trends in substance use treatment admissions for opioid use disorder among adults experiencing homelessness.
Han BH; Doran KM; Krawczyk N
J Subst Abuse Treat; 2022 Jan; 132():108504. PubMed ID: 34102461
[TBL] [Abstract][Full Text] [Related]
7. Association of Criminal Statutes for Opioid Use Disorder With Prevalence and Treatment Among Pregnant Women With Commercial Insurance in the United States.
Gressler LE; Shah S; Shaya FT
JAMA Netw Open; 2019 Mar; 2(3):e190338. PubMed ID: 30848807
[TBL] [Abstract][Full Text] [Related]
8. Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy Among Pregnant Women in Specialty Treatment.
Bachhuber MA; Mehta PK; Faherty LJ; Saloner B
Med Care; 2017 Dec; 55(12):985-990. PubMed ID: 29135769
[TBL] [Abstract][Full Text] [Related]
9. Utilization of treatment by Medicaid enrollees with opioid use disorder and co-occurring substance use disorders.
O'Brien P; Henke RM; Schaefer MB; Lin J; Creedon TB
Drug Alcohol Depend; 2020 Dec; 217():108261. PubMed ID: 32979735
[TBL] [Abstract][Full Text] [Related]
10. Recent trends in treatment admissions for prescription opioid abuse during pregnancy.
Martin CE; Longinaker N; Terplan M
J Subst Abuse Treat; 2015 Jan; 48(1):37-42. PubMed ID: 25151440
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and predictors of medication for opioid use disorder among reproductive-aged women.
Bello JK; Dell NA; Laxton AM; Conte M; Chen L
Drug Alcohol Depend Rep; 2024 Jun; 11():100239. PubMed ID: 38711835
[TBL] [Abstract][Full Text] [Related]
12. Racial/ethnic differences in medication for addiction treatment for opioid use disorders among pregnant women in treatment facilities supported by state funds.
Kitsantas P; Aljoudi SM; Baker KM; Peppard L; Oh KM
J Subst Use Addict Treat; 2023 May; 148():208960. PubMed ID: 37102193
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Initiation of Medication for Opioid Use Disorder and Retention in Treatment Among U.S. Pregnant Women, 2013-2017.
Nguemeni Tiako MJ; Friedman A; Culhane J; South E; Meisel ZF
Obstet Gynecol; 2021 Apr; 137(4):687-694. PubMed ID: 33706349
[TBL] [Abstract][Full Text] [Related]
14. Correlates of specialty substance use treatment among adults with opioid use disorders.
Romo E; Ulbricht CM; Clark RE; Lapane KL
Addict Behav; 2018 Nov; 86():96-103. PubMed ID: 29551551
[TBL] [Abstract][Full Text] [Related]
15. Prenatal intent and postpartum receipt of long-acting reversible contraception among women receiving medication-assisted treatment for opioid use disorder.
Kotha A; Chen BA; Lewis L; Dunn S; Himes KP; Krans EE
Contraception; 2019 Jan; 99(1):36-41. PubMed ID: 30114393
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
[TBL] [Abstract][Full Text] [Related]
17. The Pregnancy Recovery Center: A women-centered treatment program for pregnant and postpartum women with opioid use disorder.
Krans EE; Bobby S; England M; Gedekoh RH; Chang JC; Maguire B; Genday P; English DH
Addict Behav; 2018 Nov; 86():124-129. PubMed ID: 29884421
[TBL] [Abstract][Full Text] [Related]
18. A hidden aspect of the U.S. opioid crisis: Rise in first-time treatment admissions for older adults with opioid use disorder.
Huhn AS; Strain EC; Tompkins DA; Dunn KE
Drug Alcohol Depend; 2018 Dec; 193():142-147. PubMed ID: 30384321
[TBL] [Abstract][Full Text] [Related]
19. Trends in injection drug use among pregnant women admitted into drug treatment: 1994-2006.
Terplan M; Smith EJ; Glavin SH
J Womens Health (Larchmt); 2010 Mar; 19(3):499-505. PubMed ID: 20136556
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with buprenorphine versus methadone use in pregnancy.
Krans EE; Bogen D; Richardson G; Park SY; Dunn SL; Day N
Subst Abus; 2016; 37(4):550-557. PubMed ID: 26914546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
